Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.61 |
| ▸ | XDH | P47989 | 7/20 | 0.55 |
| ▸ | GSK3B | P49841 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875705 | 0.84 | XDH (0.74) | KDM4EHSD17B10NPC1RAB9AHTT | |
| SCHEMBL13790364 | 0.82 | KDM4E (0.72) | KDM4EHSD17B10NPC1RAB9AHTT | |
| SCHEMBL3869589 | 0.81 | KDM4E (0.71) | KDM4EHSD17B10NPC1RAB9AHTT | |
| SCHEMBL3868865 | 0.80 | KDM4E (0.75) | KDM4EHSD17B10NPC1RAB9AHTT | |
| SCHEMBL3879802 | 0.78 | KDM4E (0.71) | KDM4EHSD17B10NPC1RAB9AHTT | |
| SCHEMBL13790393 | 0.78 | NPC1 (1.00) | KDM4EHSD17B10NPC1RAB9AHTT | |
| SCHEMBL13790434 | 0.78 | KDM4E (0.71) | KDM4EHSD17B10NPC1RAB9AHTT | |
| SCHEMBL3867527 | 0.78 | KDM4E (0.67) | KDM4EHSD17B10NPC1RAB9AHTT | |
| SCHEMBL3878784 | 0.77 | KDM4E (0.70) | KDM4EHSD17B10NPC1RAB9AHTT | |
| SCHEMBL2278510 | 0.77 | ALDH1A1 (1.00) | KDM4EHSD17B10NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827444-B1 | MNK1 OR MNK2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-05-15 | — | — | EP | claimed |
| US-20090163520-A1 | MNK1 or MNK2 Inhibitors | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2009-06-25 | — | — | US | claimed |
| EP-1827444-A2 | MNK1 OR MNK2 INHIBITORS | DeveloGen Aktiengesellschaft (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1746099-A1 | Mnk1 or Mnk2 inhibitors | DeveloGen Aktiengesellschaft (DE) | 2007-01-24 | — | — | EP | claimed |
| WO-2006066937-A2 | MNK1 OR MNK2 INHIBITORS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | claimed |
| EP-1827444-B1 | MNK1 OR MNK2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20090163520-A1 | MNK1 or MNK2 Inhibitors | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163520-A1 | MNK1 or MNK2 Inhibitors | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163520-A1 | MNK1 or MNK2 Inhibitors | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2009-06-25 | — | — | US | disclosed |
| EP-1827444-A2 | MNK1 OR MNK2 INHIBITORS | DeveloGen Aktiengesellschaft (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1746099-A1 | Mnk1 or Mnk2 inhibitors | DeveloGen Aktiengesellschaft (DE) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006066937-A2 | MNK1 OR MNK2 INHIBITORS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163520-A1 | MNK1 or MNK2 Inhibitors | NEK9, CMPK1, NEK2 | KDM4E 2821/4885HSD17B10 3021/4885NPC1 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.